These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

844 related items for PubMed ID: 30972933

  • 21. 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review.
    Corfield J, Perera M, Bolton D, Lawrentschuk N.
    World J Urol; 2018 Apr; 36(4):519-527. PubMed ID: 29344682
    [Abstract] [Full Text] [Related]

  • 22. Prostate penile metastasis: Incidence and imaging pattern on 68 Ga-PSMA PET/CT.
    Tatkovic A, McBean R, Schoeman J, Wong D.
    J Med Imaging Radiat Oncol; 2020 Aug; 64(4):499-504. PubMed ID: 32449823
    [Abstract] [Full Text] [Related]

  • 23. Frusemide aids diagnostic interpretation of 68 Ga-PSMA positron emission tomography/CT in men with prostate cancer.
    Fennessy N, Lee J, Shin J, Ho B, Ali SA, Paschkewitz R, Emmett L.
    J Med Imaging Radiat Oncol; 2017 Dec; 61(6):739-744. PubMed ID: 28623852
    [Abstract] [Full Text] [Related]

  • 24. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer.
    Meijer D, Eppinga WSC, Mohede RM, Vanneste BGL, Meijnen P, Meijer OWM, Daniels LA, van den Bergh RCN, Lont AP, Ettema RH, Oudshoorn FHK, van Leeuwen PJ, van der Poel HG, Donswijk ML, Oprea-Lager DE, Schaake EE, Vis AN.
    Eur Urol Oncol; 2022 Apr; 5(2):146-152. PubMed ID: 35074282
    [Abstract] [Full Text] [Related]

  • 25. Metastatic Sites' Location and Impact on Patient Management After the Introduction of Prostate-specific Membrane Antigen Positron Emission Tomography in Newly Diagnosed and Biochemically Recurrent Prostate Cancer: A Critical Review.
    Mattana F, Muraglia L, Rajwa P, Zattoni F, Marra G, Chiu PKF, Heidegger I, Kasivisvanathan V, Kesch CV, Olivier J, Preisser F, Thibault C, Valerio M, van den Bergh RCN, Gandaglia G, Ceci F, European Association of Urology Young Academic Urologists Prostate Cancer Working Party.
    Eur Urol Oncol; 2023 Apr; 6(2):128-136. PubMed ID: 36804735
    [Abstract] [Full Text] [Related]

  • 26. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Evangelista L, Briganti A, Fanti S, Joniau S, Reske S, Schiavina R, Stief C, Thalmann GN, Picchio M.
    Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
    [Abstract] [Full Text] [Related]

  • 27. Patterns of relapse as determined by 68Ga-PSMA ligand PET/CT after radical prostatectomy : Importance for tailoring and individualizing treatment.
    Henkenberens C, Derlin T, Bengel FM, Ross TL, Wester HJ, Hueper K, Kuczyk MA, Christiansen H, von Klot CA.
    Strahlenther Onkol; 2018 Apr; 194(4):303-310. PubMed ID: 29134231
    [Abstract] [Full Text] [Related]

  • 28. Prostate Cancer: Prostate-specific Membrane Antigen Positron-emission Tomography/Computed Tomography or Positron-emission Tomography/Magnetic Resonance Imaging for Staging.
    Ferraro DA, Burger IA.
    Top Magn Reson Imaging; 2020 Feb; 29(1):59-66. PubMed ID: 32015295
    [Abstract] [Full Text] [Related]

  • 29. 18F-PSMA-11 Versus 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-over Trial.
    De Man K, Van Laeken N, Schelfhout V, Fendler WP, Lambert B, Kersemans K, Piron S, Lumen N, Decaestecker K, Fonteyne V, Delrue L, De Vos F, Ost P.
    Eur Urol; 2022 Nov; 82(5):501-509. PubMed ID: 35690515
    [Abstract] [Full Text] [Related]

  • 30. Flourodeoxyglucose positron emission tomography scan may be helpful in the case of ductal variant prostate cancer when prostate specific membrane antigen ligand positron emission tomography scan is negative.
    McEwan LM, Wong D, Yaxley J.
    J Med Imaging Radiat Oncol; 2017 Aug; 61(4):503-505. PubMed ID: 28349676
    [Abstract] [Full Text] [Related]

  • 31. Impact of piflufolastat F-18 PSMA PET imaging on clinical decision-making in prostate cancer across disease states: A retrospective review.
    Arafa AT, Jain A, Skrobanek P, Humphrey B, Froelich JW, Antonarakis ES.
    Prostate; 2023 Jun; 83(9):863-870. PubMed ID: 36999911
    [Abstract] [Full Text] [Related]

  • 32. 68Ga-PSMA-PET/CT in comparison with 18F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study.
    Dyrberg E, Hendel HW, Huynh THV, Klausen TW, Løgager VB, Madsen C, Pedersen EM, Pedersen M, Thomsen HS.
    Eur Radiol; 2019 Mar; 29(3):1221-1230. PubMed ID: 30132104
    [Abstract] [Full Text] [Related]

  • 33. The use of 68  Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer.
    Meredith G, Wong D, Yaxley J, Coughlin G, Thompson L, Kua B, Gianduzzo T.
    BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411
    [Abstract] [Full Text] [Related]

  • 34. 68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer.
    Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, Gildehaus FJ, Stief CG, Gratzke C, Fendler WP.
    Eur Urol; 2016 Oct; 70(4):553-557. PubMed ID: 26810345
    [Abstract] [Full Text] [Related]

  • 35. Application of [68Ga]PSMA PET/CT in Diagnosis and Management of Prostate Cancer Patients.
    Dadgar H, Emami F, Norouzbeigi N, Vafaee MS, Jafari E, Gholamrezanezhad A, Assadi M, Ahmadzadehfar H.
    Mol Imaging Biol; 2020 Aug; 22(4):1062-1069. PubMed ID: 31758511
    [Abstract] [Full Text] [Related]

  • 36. Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer.
    Schmuck S, Nordlohne S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, Ross TL, Bengel FM, Derlin T.
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):960-968. PubMed ID: 28280856
    [Abstract] [Full Text] [Related]

  • 37. Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study.
    Sonni I, Eiber M, Fendler WP, Alano RM, Vangala SS, Kishan AU, Nickols N, Rettig MB, Reiter RE, Czernin J, Calais J.
    J Nucl Med; 2020 Aug; 61(8):1153-1160. PubMed ID: 31924715
    [Abstract] [Full Text] [Related]

  • 38. Comparative study between 68 Ga-prostate-specific membrane antigen positron emission tomography and conventional imaging in the initial staging of prostate cancer.
    Wong HS, Leung J, Bartholomeusz D, Sutherland P, Le H, Nottage M, Iankov I, Chang JH.
    J Med Imaging Radiat Oncol; 2018 Dec; 62(6):816-822. PubMed ID: 30152050
    [Abstract] [Full Text] [Related]

  • 39. Is there a nonnegligible effect of maximum standardized uptake value in the staging and management of prostate cancer with 68Ga-prostate-specific membrane antigen positron emission tomography/computerized tomography imaging? A single-center experience.
    Ekmekcioglu O, Yavuzsan AH, Arican P, Kirecci SL.
    J Cancer Res Ther; 2021 Dec; 17(6):1351-1357. PubMed ID: 34916365
    [Abstract] [Full Text] [Related]

  • 40. [PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of 68Ga-PSMA-11 when 18F-fluorocholine is non-contributive].
    Gauthé M, Belissant O, Girard A, Zhang Yin J, Ohnona J, Cottereau AS, Nataf V, Balogova S, Pontvert D, Lebret T, Guillonneau B, Cussenot O, Talbot JN.
    Prog Urol; 2017 Dec; 27(8-9):474-481. PubMed ID: 28576423
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 43.